Q-omics provides the consensus-scored TCTE1 profile across patient tissues and cancer cell-line models. TCTE1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TCTE1 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, TCTE1 RNA expression shows 16,168 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LUAD, and ACC as cancer lineages where TCTE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCTE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCTE1 survival associations across molecular data types. TCTE1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCTE1 RNA expression–survival associations across cancer types. High TCTE1 expression shows unfavorable associations in KIRP and DLBC, but favorable associations in UVM, LGG, HNSC and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TCTE1 RNA expression.
This table summarizes TCTE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TCTE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCTE1 shows lower tumor expression in LUAD, LUSC, THCA, KICH and COAD and higher tumor expression in KIRC. The LUAD box plot shows higher TCTE1 RNA expression in normal versus tumor tissue (log2 FC = −1.407, t-test p < 0.001).
This table shows molecular features associated with TCTE1 in patient tissues and cancer cell lines. In patient samples, TCTE1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCTE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
